TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of a Modified Running-specific Prosthetic Foot

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* unilateral or bilateral, transtibial (below-knee) amputation from non-dysvascular causes~* Medicare functional classification level (K-level) 3 or higher (unlimited community ambulatory)~* prosthetic user for \> 1 year~* scheduled to receive a mRSF prosthesis~* able and willing to participate in the study protocol (e.g., treadmill walking, overground walking, respond to survey questions, able to read and write English)~Exclusion Criteria:~* contralateral lower or upper limb involvement~* any health condition that would limit participation in the study procedures (e.g., skin breakdown, heart disease)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- mRSF-ESF (Type: EXPERIMENTAL): Study participants in Arm 1 will first receive the Modified running specific foot (mRSF) and then the Energy storing foot (ESF). Outcomes will be assessed (in each condition) after 1 month of use. Order of interventions will be randomly assigned.
- ESF-mRSF (Type: EXPERIMENTAL): Study participants in Arm 2 will first receive the Energy storing foot (ESF) and then the Modified running specific foot (mRSF). Outcomes will be assessed (in each condition) after 1 month of use. Order of interventions will be randomly assigned.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics of Doxorubicin in cTACE of Liver Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 18 years.~2. Histologically, cytologically, or radiologically confirmed liver dominant or liver only malignancy.~3. Preserved liver function (Child-Pugh A-B class) without significant liver decompensation.~4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 at study entry.~5. Measurable or evaluable disease that will be directly treated with intrahepatic therapy (as defined by Response Evaluation Criteria in Solid Tumors \[RECIST\] 1.1).~6. Suitable for TACE based on blood parameters such as platelet count, bilirubin, and international normalized ratio.~7. May be enrolled with a history of prior liver directed intra-arterial therapy if intra-arterial therapy to the target lesion occured \> 1 year prior to enrollment date. Intra-arterial therapy to different targets within 1 year prior to enrollment date will not exclude subjects.~Exclusion Criteria:~1. Serum total bilirubin \> 3.0 mg/dL~2. Creatinine \> 2.0 mg/dL~3. Platelets \< 50000/µL~4. Complete portal vein thrombosis with reversal of flow~5. Ascites (trace ascites on imaging is acceptable)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- whole liver lobe cTACE doxorubicin (Type: ACTIVE_COMPARATOR): Participants in this arm are administered 10 cc of chemotherapy, with 50mg doxorubicin and 10 mg of mitomycin-C via cTACE delivered in a lobar (whole liver) manner.
- superselective cTACE doxorubicin (Type: ACTIVE_COMPARATOR): Participants in this arm are administered 10 cc of chemotherapy, with 50mg doxorubicin and 10 mg of mitomycin-C via cTACE delivered in a super-selective (close to the tumor) manner.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Women ≥ 18 and ≤ 75 years of age.~* Voluntary signed informed consent form (ICF).~* Proven diagnosis of metastatic breast cancer (MBC).~* At least one, but no more than three, prior chemotherapy regimens for MBC.~* Patients with known HER-2 overexpressing MBC must have failed at least one prior trastuzumab-containing regimen for metastatic disease.~* Disease evaluable for response by specific appropriate criteria.~* No or minimal disease-related symptoms not affecting patient daily activities.~* Adequate major organ function (normal or minimal alteration in liver, kidney, hematological, metabolic and cardiac function)~* Wash out periods prior to Day 1 of Cycle 1:~At least three weeks since the last chemotherapy (six weeks in some particular cases) and At least four weeks since the last radiotherapy (RT) \> 30 Gy) and At least one week since the last hormonal therapy and At least two weeks since the last biological/investigational therapy~* Minimal or no ongoing toxicity from immediately prior therapy according to specific appropriate criteria. Mild ongoing toxicity is allowed in case of alopecia, skin toxicity, fatigue and/or finger numbness or tumbling.~* Patients of child-bearing potential must agree to use a medically approved contraception method until at least six weeks after the last study drug administration.~* Known deleterious germline mutation of BRCA1/2 (Patients in Cohorts A and A1)~* Prior treatment with PARP inhibitors (Patients in Cohort A1)~Exclusion Criteria:~* Prior treatment with PM01183 or trabectedin.~* Extensive prior RT.~* Prior or concurrent malignant disease unless cured for more than five years.~* Exceptions are breast cancer in the other breast.~* Uncommon or rare subtypes of breast cancer.~* Symptomatic or progressive brain metastases.~* Bone-limited and exclusively metastases.~* Relevant diseases or clinical situations which may increase patient's risk:~History of cardiac disease. Moderate breathing difficulties or oxygen requirement Active uncontrolled infection. Unhealed wound or presence of any external drainage. Chronically active viral hepatitis. Immunocompromised patients, including those known to be infected by human immunodeficiency virus (HIV).~Known muscular disease or functional alteration~* Pregnant or breastfeeding women.~* Impending need for immediate RT for symptomatic relief.~* Limitation of the patient's ability to comply with the treatment or to follow-up the protocol.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- PM01183 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Fragmin for the Treatment of Acute VTE in Pediatric Cancer Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~-~Exclusion Criteria:~-

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Single Arm (Type: OTHER): Single arm open-label

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Leuprolide Acetate Injectable Suspension in the Treatment of Central Precocious Puberty

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Females age 2 to 8 years (inclusive) or males age 2 to 9 years (inclusive)~* Confirmed diagnosis of CPP within 12 months of Baseline Visit (Day 0) but have not received prior GnRH agonist treatment for CPP~* Pubertal-type LH response following an abbreviated GnRHa stimulation test before treatment initiation~* Clinical evidence of puberty, defined as Tanner stage ≥ 2 for breast development in females or testicular volume ≥ 4 mL in males~* Difference between bone age (Greulich and Pyle method) and chronological age ≥ 1 year~Exclusion Criteria:~* Gonadotropin-independent (peripheral) precocious puberty~* Prior or current GnRH treatment for CPP~* Prior or current therapy with medroxyprogesterone acetate, growth hormone or insulin-like growth factor-1 (IGF-1)~* Diagnosis of short stature (ie, 2.25 standard deviations (SD) below the mean height for age)~* Known history of seizures, epilepsy, and/or central nervous system disorders that may be associated with seizures or convulsions~* Any other medical condition or serious intercurrent illness that, in the opinion of the Investigator, may make it undesirable for the subject to participate in the study

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 9 Years
- Healthy Volunteers: f

Study Arms:
- Assigned Intervention (Type: EXPERIMENTAL): Leuprolide acetate 45 mg will be administered as a subcutaneous injection at 6-month intervals for the 12 month study period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Shock Trial: Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Men and women with myocardial infarction and cardiogenic shock.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Blood Flow Restriction Following ACL Reconstruction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 13-35 years at the time of surgery~2. Anterior Cruciate Ligament (ACL) reconstruction~3. Using a physical therapy center with Blood Flow Restriction capabilities.~Exclusion Criteria:~1. Concomitant ligament reconstruction~2. Concurrent procedures that require delayed weight bearing (ie: High Tibial Osteotomy (HTO), multi-ligament reconstruction, microfracture, etc)~3. History of Deep Vein Thrombosis (DVT)/Pulmonary Embolism (PE)~4. Immunocompromising conditions (ie: Rheumatoid arthritis, chronic steroid use, etc.)~5. History of coagulation disorders or current use of anticoagulants~6. Completion of physical therapy at a location not affiliated with the study~7. Pregnancy

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- BFR Therapy (Type: EXPERIMENTAL): This group will undergo physical therapy exercises per the standard of care, with the addition of Blood Flow Restriction (BFR) utilizing a wide pressure cuff. BFR exercises will be initiated two weeks post-op, and continued for 16 weeks.
- No BFR (Type: ACTIVE_COMPARATOR): This group of patients will undergo physical therapy exercises per the current standard of care after their ACL reconstruction without BFR

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: AccuCath Guidewire Intravenous (IV) Device Versus Conventional IV Catheter In General Nursing Use

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female, age ≥ 18 years or ≤ 89 years old;~2. Capable and willing to give informed consent;~3. English speaking;~4. Acceptable candidate for an elective, non-emergent peripheral intravenous (PIV) catheter placement as determined by ordering physician;~5. Admitted to study inpatient unit.~Exclusion Criteria:~1. Male or female, \< 18 years old or \> 89 years old;~2. Requirement for emergent IV placement (patient's condition would be compromised if there is a delay in IV placement);~3. Previous venous grafts or surgery at the target vessel access site;~4. Currently involved in other investigational clinical trials (unless permission is granted by other study principal investigator \[PI\]);~5. Females who are pregnant, planning to become pregnant within 3 months of the procedure, or lactating.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- AccuCath IV Catheter Device (Type: EXPERIMENTAL): AccuCath IV Catheter System will be used for IV therapy during inpatient stay. Intervention includes vascular access, fluid infusion, and blood sample removal
- Conventional IV Catheter Device (Type: ACTIVE_COMPARATOR): Conventional IV catheter (current catheter) will be used for IV therapy during inpatient stay. Intervention includes vascular access, fluid infusion, and blood sample removal

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combined Atropine With Orthokeratology in Childhood Myopia Control (AOK) -A Randomized Controlled Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Manifest myopia between 1.00-4.00D in both eyes at screening visit~* Manifest astigmatism ≤2.50D; with-the-rule astigmatism (axes 180 ± 30) ≤2.50D; astigmatism with other axes ≤0.50D in both eyes at screening visit~* \<1.00D difference in manifest spherical equivalent (SE) between the two eyes at screening visit~* Baseline cycloplegic objective refraction between 1.00-4.00D in sphere; astigmatism ≤2.50D; \<1.00D difference in manifest SE between the two eyes~* Best-corrected logMAR visual acuity 0.10 or better in both eyes~* Symmetrical corneal topography with corneal toricity \<2.00D in either eye~* Normal ocular health other than myopia~* Agree to be randomized and to attend the scheduled visits and aftercare~Exclusion Criteria:~* Contraindications to atropine: known allergies or cardiovascular disease, epilepsy~* Contraindications to contact lens wear and ortho-k: corneal scar, history of ocular inflammation/infection, limbus-to-limbus corneal cylinder and dislocated corneal apex~* Strabismus or amblyopia~* History of myopia control treatment (e.g. soft contact lenses, progressive add spectacles, atropine eye drops)~* Rigid contact lens (including ortho-k) wear experience~* Systemic condition which might affect refractive development (for example, Down syndrome, Marfan's syndrome)~* Ocular conditions which might affect refractive error (for example, cataract, ptosis)~* Poor response to lens wear including poor lens handling, poor vision and/ocular response after lens modifications~* Poor compliance with schedule visits

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 11 Years
- Healthy Volunteers: t

Study Arms:
- ortho-k and 0.01% atropine eye drops (Type: EXPERIMENTAL): participants will receive treatment of ortho-k and 0.01% atropine eye drops
- ortho-k (Type: ACTIVE_COMPARATOR): participants will receive treatment of ortho-k alone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of Tetanus, Diphtheria and Mono Component Acellular Pertussis (TdaP) Vaccine in Comparison to Tetanus and Diphtheria (Td) Vaccine When Given as Booster Vaccinations to Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy female or male adult of ≥ 18 years of age~2. Completed primary vaccination with diphtheria (D), Tetanus (T) and whole cell pertussis (wP) vaccines in Denmark~3. Signed informed consent~4. Prepared to grant authorised persons access to medical records~5. Likely to comply with instructions~Exclusion Criteria:~1. Congenital or acquired immunodeficiency or progressive neurologic disease~2. Uncontrolled epilepsy or progressive encephalopathy~3. Previous experience of serious adverse reaction(s) after vaccinations with diphtheria-, tetanus- acellular or whole cell pertussis- vaccines~4. Vaccinated with any diphtheria, tetanus or pertussis toxoid containing vaccine within 5 years before inclusion~5. Vaccinated with any tetanus toxoid, diphtheria toxoid or diphtheria CRM197 protein conjugated vaccine within 5 years before inclusion~6. Known tetanus-, diphtheria- or pertussis disease/infection within 5 years before inclusion~7. Known hypersensitivity or history of allergic reactions to any of the active or inactive constituents of the TdaP or Td vaccines~8. Vaccinated with a live or inactivated vaccine within 1 month before inclusion~9. Administration of immune modulating drugs (such as immunoglobulin, systemic corticosteroids, blood products, azathioprine, cyclosporine, infliximab) within 3 months before inclusion~10. Administration of any investigational drug product or vaccine within 1 month before inclusion~11. Females if pregnant or breastfeeding or not willing to use contraception during the trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- TdaP vaccine (Type: EXPERIMENTAL): None
- Td vaccine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have a diagnosis of type 2 diabetes~* Body mass index (BMI) \>=22 to \<=45 kg/m2, at screening~* Patients must be taking a stable dosage of metformin as monotherapy at screening~* Patients must have a HbA1c between \>=7% and \<=9.5% at Week 2~* Patients must have a fasting plasma glucose (FPG) \<=270 mg/dL (15 mmol/L) at Week -2~Exclusion Criteria:~* Patients having prior exposure or known contraindication or suspected hypersensitivity to JNJ-28431754, glimepiride, or metformin~* History of diabetic ketoacidosis or type 1 diabetes mellitus~* History of pancreas or beta-cell transplantation~* History of active proliferative diabetic retinopathy~* History of hereditary glucose-galactose malabsorption or primary renal glucosuria~* Renal disease requiring treatment with immunosuppressive therapy within the past 12 months before screening or a history of dialysis or renal transplant~* Taken thiazolidinedione therapy in the past 16 weeks before screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Glimepiride (Type: ACTIVE_COMPARATOR): Each patient will receive glimepiride, at protocol-specified doses, once daily in combination with protocol-specified doses of metformin for 104 weeks.
- Canagliflozin 100 mg (Type: EXPERIMENTAL): Each patient will receive 100 mg of canagliflozin (JNJ-28431754) once daily with protocol-specified doses of metformin for 104 weeks.
- Canagliflozin 300 mg (Type: EXPERIMENTAL): Each volunteer will receive 300 mg of canagliflozin (JNJ-28431754) once daily with protocol-specified doses of metformin for 104 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Impact of Sitagliptin as an Add on Therapy With Closed Loop Control in Adolescents With Diabetic Nephropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* T1DM patients aged 12-18 years with at least 5 years disease duration defined according to the criteria of International Society for Pediatric and Adolescent Diabetes (ISPAD) .~* Patients on insulin pump therapy using Medtronic advanced hybrid closed system (Medtronic, Northridge, USA) with Guardian™ 3 sensor or Guardian™ 4 sensor and Guardian link transmitter initiated at least 6 months before the study, patients with minimum daily insulin requirement of more than 8 units, willingness and ability to adhere to the study protocol, and access to the internet as well as a computer system that met requirements for uploading the study pump data.~* Active diabetic nephropathy in the form of microalbuminuria (urinary albumin excretion ) 30-299 mg/g creatinine in two of three samples over a 3- to 6-months period despite angiotensin converting enzyme inhibitors).~* Hemoglobin A1c (HbA1c) ≤8.5%.~* Patients on regular visits to clinic.~Exclusion Criteria:~* patients with other diabetic microvascular complications (neuropathy or retinopathy) or with macrovascular complications.~* Patients with history of liver disease or any disorder likely to impair liver functions or elevated liver enzymes.~* Patients with any evidence of renal impairment due to causes other than diabetes.~* Patients with hypertension.~* Hepatitis virus infection (B or C) or any evidence of infection~* Participation in a previous investigational drug study within 3 months preceding screening.~* Hypoglycemic unawareness or recurrent severe hypoglycemic episodes in the last 6 months prior to recruitment.~* Recurrent diabetic ketoacidosis (DKA) (more than 2 episodes in the previous 6 months).~* Taking other oral hypoglycemic medications which could affect blood glucose.~* Patients with known allergy to sitagliptin.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Oral sitagliptin 50 mg supplementation for three months (Type: ACTIVE_COMPARATOR): Intervention group includes: adolescents with diabetic nephropathy on advanced hybrid closed loop system receiving oral sitagliptin 50 mg for three months on a daily basis
- Control group ( No intake of oral sitagliptin 50 mg supplementation for three months) (Type: NO_INTERVENTION): Control group includes: adolescents with diabetic nephropathy on advanced hybrid closed loop system who did not take oral sitagliptin 50 mg for three months on a daily basis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete